Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 26 | 2022 | 1156 | 2.600 |
Why?
|
| Aminophenols | 4 | 2021 | 74 | 0.530 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 6 | 2021 | 422 | 0.510 |
Why?
|
| Amiloride | 1 | 2012 | 126 | 0.470 |
Why?
|
| Tobramycin | 1 | 2012 | 73 | 0.470 |
Why?
|
| Burkholderia Infections | 1 | 2012 | 42 | 0.460 |
Why?
|
| Quinolones | 4 | 2021 | 393 | 0.420 |
Why?
|
| Patient Participation | 1 | 2020 | 1447 | 0.400 |
Why?
|
| Chronic Disease | 3 | 2021 | 8992 | 0.330 |
Why?
|
| Pandemics | 3 | 2021 | 7089 | 0.260 |
Why?
|
| Bone Density | 4 | 2021 | 3395 | 0.250 |
Why?
|
| Receptors, Serotonin | 4 | 1997 | 208 | 0.240 |
Why?
|
| Benzodioxoles | 2 | 2021 | 58 | 0.230 |
Why?
|
| Radius | 2 | 2016 | 397 | 0.220 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3153 | 0.220 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3275 | 0.220 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 68 | 0.210 |
Why?
|
| Epoxide Hydrolases | 1 | 2021 | 126 | 0.210 |
Why?
|
| Men's Health | 1 | 2020 | 66 | 0.200 |
Why?
|
| Pyrrolidines | 2 | 2021 | 342 | 0.200 |
Why?
|
| Benzoates | 1 | 2021 | 240 | 0.190 |
Why?
|
| Tibia | 2 | 2016 | 1028 | 0.180 |
Why?
|
| Quipazine | 2 | 1997 | 6 | 0.170 |
Why?
|
| Breathing Exercises | 1 | 2018 | 52 | 0.170 |
Why?
|
| Respiratory Muscles | 1 | 2018 | 138 | 0.170 |
Why?
|
| Inhalation | 1 | 2018 | 149 | 0.170 |
Why?
|
| Hemoptysis | 1 | 2019 | 149 | 0.170 |
Why?
|
| Tranexamic Acid | 1 | 2019 | 143 | 0.160 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 1914 | 0.160 |
Why?
|
| Serotonin Receptor Agonists | 2 | 1997 | 158 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 2 | 2012 | 6991 | 0.150 |
Why?
|
| Women | 1 | 2018 | 224 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2016 | 774 | 0.150 |
Why?
|
| Lymphomatoid Papulosis | 1 | 1995 | 16 | 0.150 |
Why?
|
| Eating | 1 | 2022 | 1443 | 0.140 |
Why?
|
| Hypoglycemia | 1 | 2021 | 805 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 883 | 0.140 |
Why?
|
| Self Care | 1 | 2020 | 799 | 0.130 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 312 | 0.130 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2014 | 61 | 0.130 |
Why?
|
| Emergencies | 1 | 2020 | 1129 | 0.130 |
Why?
|
| Indoles | 2 | 2021 | 1857 | 0.130 |
Why?
|
| Hyperglycemia | 1 | 2022 | 1343 | 0.120 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 652 | 0.120 |
Why?
|
| Saliva | 2 | 2015 | 793 | 0.120 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 802 | 0.120 |
Why?
|
| Nose | 1 | 2016 | 488 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2015 | 695 | 0.110 |
Why?
|
| Fontan Procedure | 1 | 2018 | 762 | 0.110 |
Why?
|
| Epidermal Growth Factor | 1 | 2015 | 724 | 0.110 |
Why?
|
| Body Composition | 1 | 2022 | 2393 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 1999 | 6293 | 0.110 |
Why?
|
| Pyrazoles | 2 | 2021 | 1954 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 696 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1995 | 539 | 0.110 |
Why?
|
| Adult | 26 | 2022 | 211041 | 0.110 |
Why?
|
| Absorptiometry, Photon | 4 | 2022 | 1692 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 1776 | 0.100 |
Why?
|
| Young Adult | 13 | 2022 | 55940 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 1371 | 0.100 |
Why?
|
| Respiratory Function Tests | 3 | 2021 | 1673 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2021 | 2567 | 0.100 |
Why?
|
| Administration, Inhalation | 1 | 2012 | 1102 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2022 | 3234 | 0.090 |
Why?
|
| Asthma | 2 | 2021 | 5850 | 0.090 |
Why?
|
| Endpoint Determination | 1 | 2012 | 623 | 0.090 |
Why?
|
| Herbaspirillum | 1 | 2008 | 4 | 0.090 |
Why?
|
| Aminoglycosides | 1 | 2009 | 163 | 0.090 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2022 | 378 | 0.090 |
Why?
|
| Parents | 2 | 2021 | 3154 | 0.090 |
Why?
|
| Adolescent | 15 | 2022 | 84718 | 0.090 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 1999 | 44 | 0.090 |
Why?
|
| Child | 11 | 2021 | 73636 | 0.090 |
Why?
|
| Drug Synergism | 1 | 2012 | 1875 | 0.080 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2014 | 758 | 0.080 |
Why?
|
| Humans | 34 | 2022 | 708843 | 0.080 |
Why?
|
| Forced Expiratory Volume | 3 | 2019 | 1724 | 0.080 |
Why?
|
| Intestines | 1 | 2016 | 1929 | 0.080 |
Why?
|
| Mental Health | 1 | 2020 | 2602 | 0.080 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2008 | 225 | 0.080 |
Why?
|
| Skin Diseases | 1 | 1995 | 1088 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2012 | 2680 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2018 | 3851 | 0.070 |
Why?
|
| Sweat | 2 | 2018 | 50 | 0.070 |
Why?
|
| Exercise | 1 | 2022 | 5251 | 0.070 |
Why?
|
| Telemedicine | 1 | 2021 | 2583 | 0.070 |
Why?
|
| Desensitization, Immunologic | 1 | 2009 | 484 | 0.070 |
Why?
|
| Mass Screening | 1 | 2020 | 5182 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 3490 | 0.060 |
Why?
|
| Employment | 1 | 2010 | 1087 | 0.060 |
Why?
|
| Bronchi | 1 | 2008 | 845 | 0.060 |
Why?
|
| Pseudomonas Infections | 1 | 2008 | 620 | 0.060 |
Why?
|
| Male | 22 | 2022 | 349524 | 0.060 |
Why?
|
| Fractures, Bone | 1 | 2014 | 1849 | 0.060 |
Why?
|
| Female | 22 | 2022 | 375205 | 0.060 |
Why?
|
| Audiometry | 2 | 2016 | 249 | 0.060 |
Why?
|
| Chlorides | 2 | 2018 | 710 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 4297 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 6562 | 0.050 |
Why?
|
| Drug Hypersensitivity | 1 | 2009 | 865 | 0.050 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 1999 | 15 | 0.050 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 2 | 1997 | 76 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2021 | 11877 | 0.050 |
Why?
|
| Palatine Tonsil | 1 | 1999 | 193 | 0.050 |
Why?
|
| Inspiratory Capacity | 1 | 2018 | 40 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 10857 | 0.040 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 23020 | 0.040 |
Why?
|
| Phenylalanine | 2 | 1997 | 367 | 0.040 |
Why?
|
| 3T3 Cells | 2 | 1997 | 1126 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 1999 | 494 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 1999 | 799 | 0.040 |
Why?
|
| Bufotenin | 1 | 1997 | 1 | 0.040 |
Why?
|
| Methoxydimethyltryptamines | 1 | 1997 | 2 | 0.040 |
Why?
|
| 2,5-Dimethoxy-4-Methylamphetamine | 1 | 1997 | 3 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2022 | 21194 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2022 | 1157 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2022 | 6255 | 0.040 |
Why?
|
| Radioligand Assay | 1 | 1997 | 383 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2019 | 248 | 0.040 |
Why?
|
| Hyperplasia | 1 | 1999 | 1182 | 0.040 |
Why?
|
| Phosphatidylinositols | 1 | 1997 | 285 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 1823 | 0.040 |
Why?
|
| Ergolines | 1 | 1995 | 60 | 0.040 |
Why?
|
| Keratinocytes | 1 | 1999 | 797 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2008 | 3690 | 0.030 |
Why?
|
| Contraception | 1 | 2018 | 311 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2019 | 460 | 0.030 |
Why?
|
| Parenting | 1 | 2021 | 669 | 0.030 |
Why?
|
| DNA Primers | 1 | 1999 | 3002 | 0.030 |
Why?
|
| Models, Chemical | 1 | 1997 | 644 | 0.030 |
Why?
|
| Point Mutation | 2 | 1997 | 1656 | 0.030 |
Why?
|
| Fertility | 1 | 2018 | 712 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 412 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 1925 | 0.030 |
Why?
|
| Middle Aged | 9 | 2021 | 213752 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2019 | 936 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2018 | 41081 | 0.030 |
Why?
|
| Spirometry | 1 | 2015 | 866 | 0.030 |
Why?
|
| Time Factors | 4 | 2018 | 41038 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 1928 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 13536 | 0.030 |
Why?
|
| Immunoassay | 1 | 2015 | 766 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 2503 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2020 | 2524 | 0.030 |
Why?
|
| Vocational Guidance | 1 | 2010 | 14 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 18748 | 0.020 |
Why?
|
| Binding Sites | 2 | 1997 | 6276 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2018 | 2506 | 0.020 |
Why?
|
| Pyridines | 1 | 2021 | 2862 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2018 | 1879 | 0.020 |
Why?
|
| Caregivers | 1 | 2020 | 1906 | 0.020 |
Why?
|
| Genes, rRNA | 1 | 2008 | 77 | 0.020 |
Why?
|
| Burkholderia cepacia complex | 1 | 2008 | 24 | 0.020 |
Why?
|
| Kinetics | 1 | 1997 | 6796 | 0.020 |
Why?
|
| Transfection | 1 | 1997 | 6161 | 0.020 |
Why?
|
| Infant | 3 | 2016 | 34261 | 0.020 |
Why?
|
| United States | 3 | 2021 | 67165 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 2008 | 176 | 0.020 |
Why?
|
| Down-Regulation | 1 | 1995 | 3093 | 0.020 |
Why?
|
| Nasal Mucosa | 1 | 2010 | 369 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2018 | 2950 | 0.020 |
Why?
|
| Lung | 2 | 2022 | 9706 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2008 | 315 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2010 | 1188 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2008 | 1134 | 0.020 |
Why?
|
| Alleles | 1 | 2018 | 7090 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1997 | 6451 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 6850 | 0.020 |
Why?
|
| Base Sequence | 2 | 1995 | 13352 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 2008 | 323 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 2008 | 407 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2009 | 989 | 0.020 |
Why?
|
| DNA | 1 | 1999 | 7172 | 0.020 |
Why?
|
| Ion Channels | 1 | 2010 | 1086 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2021 | 39292 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2019 | 61932 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 7994 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 2000 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2019 | 50597 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2008 | 900 | 0.020 |
Why?
|
| Decision Making | 1 | 2018 | 3802 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 14836 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2008 | 514 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2022 | 12366 | 0.020 |
Why?
|
| Genotype | 1 | 2018 | 12863 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 16008 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 1528 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 14215 | 0.010 |
Why?
|
| Rats | 2 | 1997 | 25094 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2018 | 20170 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 20308 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2016 | 71483 | 0.010 |
Why?
|
| Aged | 3 | 2021 | 161488 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2009 | 1423 | 0.010 |
Why?
|
| Phylogeny | 1 | 2008 | 2799 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 1994 | 3033 | 0.010 |
Why?
|
| Mutation | 2 | 2018 | 29262 | 0.010 |
Why?
|
| Pregnancy | 1 | 2021 | 26832 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2008 | 1269 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 1391 | 0.010 |
Why?
|
| Host-Pathogen Interactions | 1 | 2008 | 1482 | 0.010 |
Why?
|
| Mice | 3 | 2008 | 80876 | 0.010 |
Why?
|
| Age Factors | 1 | 2015 | 18712 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 4926 | 0.010 |
Why?
|
| Ergotamine | 1 | 1995 | 7 | 0.010 |
Why?
|
| Animals | 5 | 2008 | 170486 | 0.010 |
Why?
|
| Ketanserin | 1 | 1995 | 35 | 0.010 |
Why?
|
| Amphetamines | 1 | 1995 | 150 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 13468 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 23284 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1995 | 1777 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 20320 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1995 | 1812 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1995 | 1292 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1994 | 1971 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 3209 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 69553 | 0.010 |
Why?
|
| Ligands | 1 | 1995 | 3297 | 0.010 |
Why?
|
| Models, Molecular | 1 | 1995 | 5525 | 0.000 |
Why?
|
| Protein Binding | 1 | 1995 | 9639 | 0.000 |
Why?
|
| Cell Line | 1 | 1994 | 16657 | 0.000 |
Why?
|
Concepts
(221)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(36)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_